TL;DR — Semaglutide (GLP-1 receptor agonist) and tirzepatide (dual GLP-1/GIP agonist) are FDA-approved prescription drugs backed by some of the largest cardiometabolic RCT programs ever run, for type 2 diabetes and chronic weight management. That's genuinely Tier A evidence — for those approved indications. "Longevity" is a real but separate extrapolation from the weight-loss and cardiovascular-outcome data, not itself a trial endpoint, and both remain prescription-only.
What semaglutide and tirzepatide are, and how they differ
Both drugs work by mimicking incretinA gut hormone (like GLP-1 or GIP) released after eating that regulates insulin secretion, gastric emptying, and appetite. Full glossary → hormones — the gut signals that regulate insulin secretion, gastric emptying, and appetite after eating:
- Semaglutide (marketed as Ozempic and Rybelsus for diabetes, Wegovy for weight management) is a GLP-1 receptor agonist.
- Tirzepatide (marketed as Mounjaro for diabetes, Zepbound for weight management) is a dual GLP-1/GIP receptor agonist — it additionally engages the GIP receptor, which appears to produce somewhat larger average weight-loss effects in head-to-head trial comparisons.
Both are injectable (semaglutide also has an oral formulation, Rybelsus), once-weekly dosed, and titrated upward over weeks to months to manage GI side effects.
Primary hallmarks targeted: Deregulated nutrient sensing · Chronic inflammation (via metabolic improvement)
The STEP trial program (Wilding et al., New England Journal of Medicine, 2021, and subsequent STEP trials) established semaglutide's weight-loss efficacy in adults with obesity. The SURMOUNT trial program (Jastreboff et al., New England Journal of Medicine, 2022, and subsequent SURMOUNT trials) established tirzepatide's efficacy, with larger average weight-loss effects than semaglutide in comparative analyses. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) specifically tested semaglutide for cardiovascular-outcome reduction in adults with overweight/obesity and established cardiovascular disease but without diabetes — a genuinely different and important trial, since it targeted cardiovascular events directly, not just weight loss. This is a large, replicated, multi-trial human RCT evidence base.
Mechanism — incretin-receptor agonism, appetite regulation, and downstream metabolic effects
| Reported effect | Trial evidence | Hallmark link |
|---|---|---|
| Significant sustained weight loss | STEP, SURMOUNT programs | Nutrient sensing |
| Improved glycemic control | Original diabetes-indication trials | Nutrient sensing |
| Reduced major adverse cardiovascular events | SELECT trial (semaglutide) | Chronic inflammation, nutrient sensing |
| Improved markers of systemic inflammation | Secondary analyses across trial programs | Chronic inflammation |
The mechanism runs through appetite suppression (via central GLP-1/GIP receptor effects), slowed gastric emptying, and improved insulin sensitivity — well-characterized pharmacology, not a novel or speculative one. What's genuinely new and relevant to a longevity discussion is the SELECT trial's finding: cardiovascular event reduction in people without diabetes, suggesting a benefit that isn't purely downstream of glycemic control.
The longevity extrapolation — what the trials show vs. what 'anti-aging' claims add
The trials show: significant weight loss, improved glycemic control, and reduced cardiovascular events in specific, well-defined populations. What "anti-aging" marketing adds on top: an inference that these metabolic/cardiovascular improvements will translate into a longer healthspanThe portion of life spent in good health, free from chronic disease or disability — distinct from lifespan (total years alive). Full glossary → generally, including in people without obesity, diabetes, or cardiovascular disease. That inference is plausible — improving metabolic health broadly correlates with healthier aging — but it has not itself been the subject of a longevity-specific trial, and "off-label use in a metabolically healthy person for anti-aging" is a materially different risk-benefit calculation than the trials actually ran.
Evidence summary
| Trial | Drug | Population | Key outcome | Tier |
|---|---|---|---|---|
| STEP program (Wilding et al., NEJM 2021 + follow-ups) | Semaglutide | Adults with obesity | Significant sustained weight loss | A |
| SURMOUNT program (Jastreboff et al., NEJM 2022 + follow-ups) | Tirzepatide | Adults with obesity | Larger average weight loss vs. semaglutide in comparative data | A |
| SELECT (Lincoff et al., NEJM 2023) | Semaglutide | Overweight/obese adults with established CVD, no diabetes | Reduced major adverse cardiovascular events | A |
| Dedicated longevity/healthspan RCT | Either | General population | None published | — |
← Swipe for more columns →
Does the longevity case apply to you specifically?
Do you have obesity, type 2 diabetes, or established cardiovascular disease with overweight/obesity?
You fall within populations the actual trial evidence covers — this is a genuine physician-prescribed treatment conversation, not an extrapolation.
Recognize that off-label use for general "anti-aging" in a metabolically healthy person extrapolates beyond the populations these landmark trials studied.
Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 — both are established contraindications in FDA labeling, not theoretical concerns.
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
The longevity extrapolation — what the trials show vs. what "anti-aging" claims add
Because both drugs are prescription-only, the practical sourcing question differs entirely from every other peptideA short chain of amino acids — smaller than a full protein — that usually acts on a specific cell-surface receptor rather than a broad metabolic pathway. Full glossary → on this list: the legitimate pathway is a physician prescription and pharmacy dispensing, evaluated against your actual metabolic and cardiovascular risk profile — not a research-chemical vendor. Compounded/gray-market versions of semaglutide and tirzepatide have circulated during supply shortages and carry real, documented purity and dosing-accuracy problems the FDA has issued specific warnings about.
Real, FDA-labeled risks — not peptide-forum speculation
- Medullary thyroid carcinoma / MEN2 history — established contraindication in FDA labeling for both drugs, based on rodent thyroid C-cell tumor signal.
- Pancreatitis — a recognized, if uncommon, adverse effect requiring discontinuation if symptoms occur.
- Compounded/gray-market versions — the FDA has issued specific warnings about dosing errors and contamination in compounded semaglutide/tirzepatide during supply shortages; this is a documented, not theoretical, risk.
- GI side effects — nausea, vomiting, and constipation are common, dose-dependent, and the primary reason for the slow titration schedule.
Safety, red flags, and contraindications
- Absolute contraindication: personal or family history of medullary thyroid carcinoma or MEN2.
- Discontinue and seek care for severe, persistent abdominal pain (possible pancreatitis).
- Use FDA-regulated pharmacy-dispensed product, not compounded or gray-market versions, given documented dosing/contamination issues with the latter.
- Requires physician oversight for dose titration — starting at label-recommended doses and titrating too quickly is the most common cause of severe GI side effects.
Personal tracking template
My GLP-1/GIP tracking log
| Date | Week | Weight | Fasting glucose | HbA1c | GI side effects (0–10) | Notes |
|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | Baseline before starting, physician-supervised |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: Progressive weight loss and/or glycemic improvement consistent with trial-reported trajectories, tolerable GI side effects. - No effect: No change after adequate titration period — discuss dose/formulation with physician. - Stop and reassess: Severe abdominal pain, signs of pancreatitis, or any thyroid-related symptom.
Track metabolic markers alongside a prescribed protocol
Fasting glucose, HbA1c, and weight are the exact markers the landmark trials measured — track the same ones.
Open Labs Hub